Patient Safety and Quality Improvement Act of 2005
- 期刊名称Annals of Pharmacotherapy
- 作者Fassett, W. E
- 卷第40卷
- 期第5期
- 印刷ISSN1060-0280
- 电子ISSN1542-6270
- 文件大小83.06KB
- 发表时间2006-05-02
- DOI10.1345/aph.1g485
- 页码917-924
Atazanavir urolithiasis without recent intake of atazanavirBrunel, Valery; Massy, Nathalie; Malval, Benoit · Annales de Biologie Clinique · 2019
Interaction between buprenorphine and atazanavir or atazanavir/ritonavirElinore F. McCance-Katz; David E. Moody; Gene D. Morse; Qing Ma; Robin DiFrancesco; Gerald Friedland; Patricia Pade; Petrie M. Rainey · 2007
Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reductionM Giola; M Cusato; P Villani; C Basilico; D Bernasconi De Luca; L Lazzaroni; L Rizzi; PA Grossi · 2008
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsSquires, Kathleen E; Young, Benjamin; DeJesus, Edwin; Bellos, Nicholaos; Murphy, Daniel; Zhao, Henry H; Patel, Lisa G; Ross, Lisa L; Wannamaker, Paul G; Shaefer, Mark S · AIDS · 2010
Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogsCheng, Changfu; Vedananda, Sunanda; Wu, Lijun; Harbeson, Scott; Braman, Virginia; Tung, Roger · Journal of Mass Spectrometry · 2013
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescentsKiser, Jennifer J.; Rutstein, Richard M.; Samson, Pearl; Graham, Bobbie; Aldrovandi, Grace; Mofenson, Lynne M.; Smith, Elizabeth; Schnittman, Steven; Fenton, Terry; Brundage, Richard C.; Fletcher, Courtney V. · AIDS · 2011
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and RitonavirSevinsky, Heather; Zaru, Luna; Wang, Reena; Xu, Xiaohui; Pikora, Cheryl; Correll, Todd A.; Eley, Timothy · The Pediatric Infectious Disease Journal · 2017
External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected PatientsDinko Rekić, Daniel Röshammar, Martin Bergstrand, Joel Tarning… · 2013
Critical Behavior of the Two-Dimensional Ising SusceptibilityOrrick, W. P.; Nickel, B. G.; Guttmann, A. J.; Perk, J. H. H. · Physical Review Letters · 2001
An In-Depth Analysis of Medication Errors in Hospitalized Patients with HIVSnyder, A. M.; Klinker, K.; Orrick, J. J.; Janelle, J.; Winterstein, A. G. · Annals of Pharmacotherapy · 2011
Identifying Subgroups of Care Providers Participating in a Telehealth Educational Intervention: Hierarchical Cluster Analysis of Evaluation DataWao, H.; Beckstead, J. W.; Beal, J.; Aluoch, M.; Skipper, T. C.; Orrick, J. J. · Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2015
Infliximab Treatment of SarcoidosisSerio, Ryan N · The Annals of Pharmacotherapy · 2003
Community Pharmacy Services in PortugalCosta, S.; Santos, C.; Silveira, J. · Annals of Pharmacotherapy · 2006
Bioavailability of DigoxinFrancke, D. E · Annals of Pharmacotherapy · 2006
Nelfinavir mesylate: a protease inhibitorPai, V. · Annals of Pharmacotherapy · 1999
Pharmacoeconomics: Historical PerspectiveBootman, J L. · Annals of Pharmacotherapy · 2006
Handbook of Anticancer Pharmacokinetics and PharmacodynamicsGwilt, P. R · Annals of Pharmacotherapy · 2004
Mifepristone: Less Obvious Adverse EffectsRudd, Gene · The Annals of Pharmacotherapy · 2001
Pharmaceutical Care, 2nd EditionJones, Mark · The Annals of Pharmacotherapy · 2003